Physician profile
Anthony Stewart Stack
NPI 1528562832
$3,469.85
in general payments reported to CMS, 2019-2025
26 companies · $911 in 2025
The $911 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $208 · 2022: $99.99 · 2023: $998 · 2024: $1,146 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595 · Education: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.24 |
| Education | $460.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $560.25 | 2019-2023 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $558.58 | 2023-2025 | Tagrisso, Enhertu, Imfinzi |
| Exelixis INC. | $432.63 | 2023-2024 | Cabometyx |
| Janssen Biotech, INC. | $345.32 | 2024-2025 | Carvykti, Darzalex, Tecvayli |
| Seagen INC. | $298.98 | 2022-2023 | |
| Daiichi Sankyo INC. | $221.51 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $157.60 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $155.25 | 2021-2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $122.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $106.22 | 2024-2025 | |
| Incyte Corporation | $55.50 | 2025 | Jakafi, Monjuvi |
| Lilly USA, LLC | $52.81 | 2024-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $49.65 | 2025 | Trodelvy |
| Tempus Ai, INC | $45.07 | 2025 | Xt Cdx |
| Abbvie INC. | $42.12 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $29.03 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $28.50 | 2024 | Jemperli, Zejula |
| Agios Pharmaceuticals, INC. | $27.05 | 2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $27.00 | 2025 | Monoferric |
| Astellas Pharma US INC | $25.53 | 2024 | Xtandi |
| Legend Biotech USA INC. | $25.11 | 2025 | Carvykti |
| Sobi, INC | $23.19 | 2024 | |
| Sumitomo Pharma America, INC. | $22.84 | 2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $21.76 | 2025 | |
| Puma Biotechnology, INC. | $19.93 | 2024 | |
| Angiodynamics, INC. | $15.98 | 2025 | Solero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.